Highlights
- The new ALS biorepository offers the world’s largest collection of patient-specific iPSCs and multi-omics data for research.
- Over 1,800 iPSC lines have already been shared with more than 130 institutions globally, advancing ALS research efforts.
- This platform’s rich multi-omics dataset and rapid motor neuron generation offer key insights for personalized ALS therapies.
In a major development for ALS (amyotrophic lateral sclerosis) research, Answer ALS and Cedars-Sinai have launched the world’s largest repository of patient-derived induced pluripotent stem cells (iPSCs) and related clinical data. This extensive collection includes biological and clinical data from nearly 1,000 ALS patients, providing a rich resource for researchers globally. The team behind this achievement, led by Dr. Dhruv Sareen at the Cedars-Sinai Biomanufacturing Center, has developed patient-specific motor neurons derived from reprogrammed blood cells, offering a novel way to study ALS mechanisms.
The iPSCs, which can be differentiated into motor neurons, reflect the full complexity of ALS by capturing not only genetic but also epigenetic, transcriptomic, and proteomic profiles unique to each patient. These characteristics are key for understanding the progression of ALS and tailoring personalized treatments. Researchers across academia and industry now have access to this cutting-edge model through the Answer ALS Neuromine Data Portal and Cedars-Sinai’s Biomanufacturing Center, which makes these resources available globally.
Clive Svendsen, Director at Cedars-Sinai’s Regenerative Medicine Institute, emphasized the unprecedented nature of the project, highlighting how this biorepository will support research into ALS pathogenesis and therapeutic strategies. The availability of patient-specific iPSCs provides a significant advantage over traditional models, which have limitations in replicating the complexity of human biology.
Already, over 1,800 cell lines have been distributed to more than 130 institutions worldwide, including universities and pharmaceutical companies. With the repository’s open-access model, these resources are poised to accelerate ALS research and the development of effective treatments, contributing to the global fight against this devastating disease.
Clare Durrett, Managing Director of Answer ALS, pointed out the critical importance of this biorepository, noting its potential to fast-track drug discovery. The platform’s ability to generate motor neurons in a fraction of the time compared to conventional methods is a crucial step forward in ALS research, offering hope for those affected by the disease.
About the Author
Biobanking.com delivers valuable news and information on biobanking, biorepositories, cryopreservation, and sample/biospecimen management, while connects buyers with top vendors globally.
